Nanoscale sensor detects lung cancer through breath chemistry

Exhaled breath contains chemical clues to what’s going on inside the body, including diseases like lung cancer.

Structure’s oral GLP-1 produces comparable weight loss to Lilly’s oral candidate

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 4, 2024

MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials. – Biotech Investments

EQS Newswire / 17/01/2024 / 14:25 UTC+8 MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2)

January 18, 2024

Regeneron hit with FDA rejection for blood cancer therapy – Pharmaceutical Technology

Share this article The biotech was pursuing indications in relapsed/refractory follicular lymphoma and in relapsed/refractory diffuse large B-cell lymphoma. Image credit: Shutterstock/Kateryna Kon. The US

March 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.